2 new PET tracers may best FDG in cancer imaging

By Wayne Forrest, AuntMinnie.com contributing writer
March 14, 2019

Cancer detection could receive a boost from two new radiotracers that have achieved substantially shorter image acquisition times than FDG-PET scans and required no fasting or dietary changes, according to a proof-of-concept study published in the March issue of the Journal of Nuclear Medicine.

The radiotracers are based on gallium-68 (Ga-68) and act as a fibroblast activation protein inhibitor (FAPI). They are considered a new class of radiopharmaceutical, designed to target cancer-associated fibroblasts, which promote tumor growth, migration, and progression. In fact, fibroblast activation proteins are present in more than 90% of epithelial carcinomas -- including breast, lung, colon, pancreatic, and head and neck cancers -- making them a viable option for both diagnostic imaging and therapy.

"Having an additional diagnostic tool opens up a new door for cancer patients," added study co-author Dr. Uwe Haberkorn, professor of nuclear medicine at the University Hospital Heidelberg and the German Cancer Research Center in Heidelberg, in a statement. "For those who are facing unmet diagnostic challenges -- unclear tumor segmentation for radiation therapy, suspicion of false-negative findings, or selection of last-line experimental treatment -- Ga-68 FAPI may help to provide answers."

In this study, the researchers used Ga-68 FAPI in scans of 50 patients who appeared to have an abundance of fibroblast activation proteins and whose conditions could not be definitively diagnosed through conventional means. Preliminary dosimetry estimates for Ga-68 FAPI-2 and Ga-68 FAPI-4 were based on two patients who were examined 10 minutes, one hour, and three hours after tracer injection. PET/CT scans (Biograph mCT Flow, Siemens Healthineers) of tumor patients were acquired one hour after injection, with 25 subjects given Ga-68 FAPI-2 and the other 25 administered Ga-68 FAPI-4 (J Nucl Med, March 2019, Vol. 60:3, pp. 386-392).

PET images of Ga-68 FAPI-2 and Ga-68 FAPI-4
PET images of Ga-68 FAPI-2 and Ga-68 FAPI-4 were obtained at 10 minutes, one hour, and three hours after injection. Rapid tumor targeting and fast blood clearance are followed by a long plateau phase without relevant change in image contrast (top). In comparison with Ga-68 FAPI-2, Ga-68 FAPI-4 is characterized by a prolonged tumor retention time (bottom). LW = lumbar body. Images courtesy of Giesel et al and the J Nucl Med.

The tracers provided high-contrast images with quality equal to or better than that of the standard FDG-PET/CT imaging, without the need for patients to undergo any dietary restrictions or a fasting regimen before the scans. All of the patients tolerated the examination well, with no reports of any adverse symptoms or reactions.

The researchers also reported a fast clearance through the kidneys; normal organs showed low tracer uptake with only minimal changes between 10 minutes and three hours after injection. With Ga-68 FAPI-2, tumor uptake decreased by 75% from one to three hours after injection, while tumor retention was prolonged with Ga-68 FAPI-4 (25% washout). Faster tracer kinetics also made it "appropriate for imaging patients even less than one hour after injection," the team wrote.

"A shorter waiting time and shorter scan time can increase patient comfort, which can be especially important for sick patients," Haberkorn added. "The possibility of early imaging -- for example, after only 10 minutes instead of an hour -- could also play a part in simplifying clinical workflow."

Given these preliminary findings, the researchers are hopeful FAPI PET imaging someday may be used to assess and manage cardiac diseases or fibrotic diseases of the lung, liver, and kidneys.

Later PET/CT follow-up helps for oropharyngeal cancer
Using PET/CT for follow-up at a later interval than what's recommended by existing guidelines can potentially adjust the management of patients who have...
Ga-68 PSMA-11 PET/MRI improves prostate cancer detection
VIENNA - PET/MRI with the radiopharmaceutical gallium-68 (Ga-68) prostate-specific membrane antigen-11 (PSMA-11) could become a valuable tool in image-guided...
New PET tracer could aid melanoma detection
A new PET tracer designed to target melanin pigment could improve the detection of both primary and metastatic melanoma, according to a study published...
FDG-PET/CT fails for peripheral T-cell lymphoma outcomes
Don't expect much help from FDG-PET/CT results in predicting progression-free or overall survival among patients with peripheral T-cell lymphoma, according...
PET/CT predicts success of rad therapy for spinal mets
FDG-PET/CT scans can predict the success of radiation therapy in patients with spinal metastases, especially in regard to progression-free survival, according...

Copyright © 2019 AuntMinnie.com

Last Updated np 3/21/2019 10:18:55 AM